Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B
The experimentally established mechanism targets of Gemcitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 known ✓ | P09884 | 2/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.91 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.91 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.91 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.56 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.56 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.56 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.46 |
| ▸ | ALB | P02768 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | CDA | P32320 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemcitabine SCHEMBL285130 | 1.00 | PDE3A (0.91) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL17978348 | 1.00 | PDE3A (0.91) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL350020 | 1.00 | PDE3A (0.91) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL28334969 | 0.99 | PDE3A (0.89) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL19137411 | 0.97 | PDE3A (0.85) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL3975223 | 0.97 | PDE3A (0.89) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL6761683 | 0.95 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL6369622 | 0.95 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL20827751 | 0.95 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL12737233 | 0.95 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048152-A1 | GEMCITABINE INORGANIC-ORGANIC HYBRID NANOPARTICLES | KARLSRUHER INSTITUT FUER TECH KOERPERSCHAFT DES OEFFENTLICHEN RECHTS (DE) | 2026-02-19 | — | — | US | claimed |
| US-20250082664-A1 | NUCLEOSIDE FORMULATION | PHION THERAPEUTICS LTD. (GB) | 2025-03-13 | — | — | US | claimed |
| US-20250025426-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2025-01-23 | — | — | US | claimed |
| WO-2024221952-A1 | NANO-DELIVERY SYSTEM OF NUCLEOTIDE DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院苏州纳米技术与纳米仿生研究所 | 2024-10-31 | — | — | WO | claimed |
| CN-118831053-A | Nanometer delivery system of nucleotide drug and preparation method and application thereof | 中国科学院苏州纳米技术与纳米仿生研究所 | 2024-10-25 | — | — | CN | claimed |
| EP-4448014-A1 | NUCLEOSIDE FORMULATION | Phion Therapeutics Limited (GB) | 2024-10-23 | — | — | EP | claimed |
| EP-4444275-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2024-10-16 | — | — | EP | claimed |
| CN-118742327-A | Nucleoside formulations | 飞昂治疗有限公司 | 2024-10-01 | — | — | CN | claimed |
| WO-2023111147-A1 | NUCLEOSIDE FORMULATION | PHION THERAPEUTICS LTD (GB) | 2023-06-22 | — | — | WO | claimed |
| WO-2023104380-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2023-06-15 | — | — | WO | claimed |
| EP-4190312-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE AGENTS INTO NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2023-06-07 | — | — | EP | claimed |
| CN-115708833-A | Application of gemcitabine in preparation of anti-hydatid medicament | 四川大学 | 2023-02-24 | — | — | CN | claimed |
| CN-114796468-A | Gemcitabine compound and CAR-T cell targeting NKG2D ligand for preparing medicine for treating malignant tumor | 深圳宾德生物技术有限公司 | 2022-07-29 | — | — | CN | claimed |
| US-20070025910-A1 | Anticancer therapy | REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2007-02-01 | — | — | US | claimed |
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260048152-A1 | GEMCITABINE INORGANIC-ORGANIC HYBRID NANOPARTICLES | KARLSRUHER INSTITUT FUER TECH KOERPERSCHAFT DES OEFFENTLICHEN RECHTS (DE) | 2026-02-19 | — | — | US | disclosed |
| US-20260048152-A1 | GEMCITABINE INORGANIC-ORGANIC HYBRID NANOPARTICLES | KARLSRUHER INSTITUT FUER TECH KOERPERSCHAFT DES OEFFENTLICHEN RECHTS (DE) | 2026-02-19 | — | — | US | disclosed |
| US-20020086812-A1 | Methods and compositions for diagnosis and treatment of cancer | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2002-07-04 | — | — | US | disclosed |
| US-20020068743-A1 | Composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer | PFIZER ENTERPRISES SARL (LU) | 2002-06-06 | — | — | US | disclosed |
| WO-2001062235-A2 | A COMPOSITION COMPRISING CAMPTOTHECIN AND A PYRIMIDINE DERIVATIVE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA S.A. (FR) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | RNGTT, CDA, DCTD | POLA1 49/4885PDE3A 1610/4885PDE4D 537/4885 |
| US-20020068743-A1 | Composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer | TYMP, TOP1, DPYD | POLA1 91/4885PDE3A 120/4885PDE4D 99/4885 |
| US-20250082664-A1 | NUCLEOSIDE FORMULATION | SLC29A1, SLC29A2, PNP | POLA1 1267/4885PDE3A 546/4885PDE4D 562/4885 |
| US-20260048152-A1 | GEMCITABINE INORGANIC-ORGANIC HYBRID NANOPARTICLES | GOT1, RNMT, GNAO1 | POLA1 102/4885PDE3A 936/4885PDE4D 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.